Rawan Faramand

1.9k total citations
37 papers, 375 citations indexed

About

Rawan Faramand is a scholar working on Oncology, Hematology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Rawan Faramand has authored 37 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 15 papers in Hematology and 9 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Rawan Faramand's work include CAR-T cell therapy research (17 papers), Acute Lymphoblastic Leukemia research (9 papers) and Acute Myeloid Leukemia Research (8 papers). Rawan Faramand is often cited by papers focused on CAR-T cell therapy research (17 papers), Acute Lymphoblastic Leukemia research (9 papers) and Acute Myeloid Leukemia Research (8 papers). Rawan Faramand collaborates with scholars based in United States, Australia and Canada. Rawan Faramand's co-authors include Marco L. Davila, Emiliano Roselli, Ashkan Emadi, Amir Fathi, Seth A. Wander, Rena G. Lapidus, Seda S. Tolu, Eunice S. Wang, Frederick L. Locke and Brandon Carter‐Cooper and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rawan Faramand

34 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rawan Faramand United States	10	210	154	115	59	57	37	375
Xinjie Xu United States	9	290 1.4×	160 1.0×	96 0.8×	118 2.0×	99 1.7×	35	483
Andrea Pepper United Kingdom	8	187 0.9×	121 0.8×	96 0.8×	42 0.7×	132 2.3×	19	348
Adam J. Lamble United States	12	282 1.3×	159 1.0×	256 2.2×	57 1.0×	147 2.6×	54	548
Elizabeth Budde United States	9	161 0.8×	105 0.7×	88 0.8×	28 0.5×	48 0.8×	26	275
Alessandro Previtali United States	7	257 1.2×	84 0.5×	101 0.9×	47 0.8×	76 1.3×	18	374
Kyogo Suzuki Japan	6	185 0.9×	167 1.1×	69 0.6×	44 0.7×	80 1.4×	15	333
Sabarinath Venniyil Radhakrishnan United States	12	219 1.0×	119 0.8×	128 1.1×	38 0.6×	112 2.0×	28	332
Jairo Matthews United States	9	94 0.4×	223 1.4×	166 1.4×	19 0.3×	39 0.7×	22	403
Zhongxing Jiang China	13	118 0.6×	164 1.1×	81 0.7×	32 0.5×	113 2.0×	28	364
Thomas Mika Germany	11	151 0.7×	80 0.5×	68 0.6×	28 0.5×	39 0.7×	27	295

Countries citing papers authored by Rawan Faramand

Since Specialization

Citations

This map shows the geographic impact of Rawan Faramand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rawan Faramand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rawan Faramand more than expected).

Fields of papers citing papers by Rawan Faramand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rawan Faramand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rawan Faramand. The network helps show where Rawan Faramand may publish in the future.

Co-authorship network of co-authors of Rawan Faramand

This figure shows the co-authorship network connecting the top 25 collaborators of Rawan Faramand. A scholar is included among the top collaborators of Rawan Faramand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rawan Faramand. Rawan Faramand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faramand, Rawan & Frederick L. Locke. (2025). Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL. Nature Reviews Clinical Oncology. 22(3). 161–162. 1 indexed citations

Ghobadi, Armin, Ibrahim Aldoss, Shannon L. Maude, et al.. (2024). Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL). Transplantation and Cellular Therapy. 30(2). S14–S15. 1 indexed citations

Srour, Samer A., Jeremy Pantin, Sagar S. Patel, et al.. (2024). AML-521 Treatment of Acute Myeloid Leukemia With Orca-T. Clinical Lymphoma Myeloma & Leukemia. 24. S317–S317. 1 indexed citations

Albanyan, Omar, Hany Elmariah, Jongphil Kim, et al.. (2024). Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplantation and Cellular Therapy. 30(11). 1090.e1–1090.e10.

Ionescu, Filip, David A. Sallman, Kendra Sweet, et al.. (2024). Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 24(6). 400–406. 2 indexed citations

Buro, Acadia W., et al.. (2024). Sexual Health Among Young Adults Treated with Chimeric Antigen Receptor T Cell Therapy: A Mixed-Methods Study. Journal of Adolescent and Young Adult Oncology. 14(3). 244–252.

Sallman, David A., Amy F. McLemore, Rami S. Komrokji, et al.. (2024). Measurable Residual Disease Monitoring By Duplex Sequencing for TP53 in the Post Allogeneic Stem Cell Transplantation Study with Eprenetapopt (APR-246) + Azacitidine Strongly Predicts Outcomes. Blood. 144(Supplement 1). 1046–1046. 1 indexed citations

Liveringhouse, Casey, Nicholas Figura, Joseph Weygand, et al.. (2023). Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation. Technology in Cancer Research & Treatment. 22. 2223922667–2223922667. 4 indexed citations

Pidala, Joseph, Shernan G. Holtan, Kelly Walton, et al.. (2023). JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results. Blood. 142(Supplement 1). 2177–2177. 1 indexed citations

10.

Gonzalez, Rebecca, Joseph Pidala, Aleksandr Lazaryan, et al.. (2023). Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. 29(9). 577.e1–577.e9. 5 indexed citations

11.

Roloff, Gregory W., Rawan Faramand, Ibrahim Aldoss, et al.. (2023). Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.. Journal of Clinical Oncology. 41(16_suppl). 7001–7001. 8 indexed citations

12.

Jain, Michael D., Bachisio Ziccheddu, Caroline A. Coughlin, et al.. (2022). Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 140(5). 491–503. 36 indexed citations

13.

Pidala, Joseph, Kelly Walton, Hany Elmariah, et al.. (2021). Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clinical Cancer Research. 27(10). 2712–2722. 15 indexed citations

14.

Mokhtari, Sepideh, Jeffrey A. Silverman, Kayla Reid, et al.. (2021). Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. SHILAP Revista de lepidopterología. 3(1). 223–227. 10 indexed citations

15.

Faramand, Rawan, et al.. (2021). Toxicities associated with adoptive cellular therapies. Best Practice & Research Clinical Haematology. 34(3). 101287–101287. 9 indexed citations

16.

Roselli, Emiliano, Rawan Faramand, & Marco L. Davila. (2021). Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. Journal of Clinical Investigation. 131(2). 65 indexed citations

17.

Mirza, Abu‐Sayeef, Ambuj Kumar, Hamza Hashmi, et al.. (2020). Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy. 27(3). 242.e1–242.e6. 7 indexed citations

18.

Jain, Michael D., Meghan Menges, Rawan Faramand, et al.. (2019). Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma. Blood. 134(Supplement_1). 2885–2885. 9 indexed citations

19.

Babakoohi, Shahab, Rena G. Lapidus, Rawan Faramand, Edward A. Sausville, & Ashkan Emadi. (2016). Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms. Applied immunohistochemistry & molecular morphology. 25(5). 334–337. 4 indexed citations

20.

Fathi, Amir, Seth A. Wander, Rawan Faramand, & Ashkan Emadi. (2015). Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology. 52(3). 165–171. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact